Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced ...

Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...

U.S. stock futures are pointing higher ahead of wholesale inflation data, China mulls selling TikTok to Elon Musk, and ...

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Today’s drop in Moderna’s price moves the company’s stock to its lowest levels since April 2020. Shares now trade 93% lower ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...